| Popis: |
Aim. The aim of the work was to study for three years the dynamics of matrix metalloproteinase 9 in patients with comorbid pathology who had suffered a myocardial infarction with ST segment elevation. Materials and methods. The study included patients of both sexes older than 18 years. All of them signed an informed consent for participation in the study. The inclusion criteria, in addition to signing informed consent for participation in the study, were acute myocardial infarction with ST elevation (STEMI), PCI and implantation of 1-2 stents into the left coronary artery, the presence of hypertension, type 2 diabetes melitus. Patients younger than 18 years and older than 80 years with type 1 diabetes mellitus, the presence of oncological diseases at the time of the study or in the anamnesis, chronic obstructive pulmonary disease, chronic viral infections were not included. All diagnoses were established according current clinical recommendations. The patients were divided into two groups. The first group included patients with arterial hypertension and type 2 diabetes mellitus, the second group included patients who had suffered acute myocardial infarction with ST segment elevation, who had arterial hypertension and type 2 diabetes mellitus. Serum was used to assess the content of matrix metalloproteinase 9. A standard test kit was used ("Cloud-Clone Corp.", China) in accordance with the instructions. The calculations were carried out using Excel spreadsheets and the statistical software package Statistica 10 (StatSoftInc.) USA. Results. When studying the level of metalloproteinase 9 for 3 years in patients who had suffered a myocardial infarction, it was found that the level of MMP-9 was statistically significantly higher in patients at the time of hospitalization, then decreased by the first year after the index event and became comparable with patients who did not have MI. After 36 months from the start of the study, patients who had suffered a myocardial infarction had statistically significantly higher levels of matrix metalloproteinase 9, compared with their values by the end of the first year, however, these data are comparable to the level of MMP-9 in patients of the first group. The level of MMP-9 in the first group is comparable at all time stages of observation. Conclusion. The inflammatory marker MMP-9, under certain conditions, can serve as a good predictor for predicting fatal outcomes and repeated AMI in patients who have undergone MI. |
